Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.
Trends Pharmacol Sci
; 36(12): 822-846, 2015 Dec.
Article
en En
| MEDLINE
| ID: mdl-26538316
ABSTRACT
Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast cancers that have a poor clinical outcome. Although no approved targeted therapy is available for TNBCs, molecular-profiling efforts have revealed promising molecular targets, with several candidate compounds having now entered clinical trials for TNBC patients. However, initial results remain modest, thereby highlighting challenges potentially involving intra- and intertumoral heterogeneity and acquisition of therapy resistance. We present a comprehensive review on emerging targeted therapies for treating TNBCs, including the promising approach of immunotherapy and the prognostic value of tumor-infiltrating lymphocytes. We discuss the impact of pathway rewiring in the acquisition of drug resistance, and the prospect of employing combination therapy strategies to overcome challenges towards identifying clinically-viable targeted treatment options for TNBC.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama Triple Negativas
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Trends Pharmacol Sci
Año:
2015
Tipo del documento:
Article